Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 679

1.

Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis.

Yap KS, Ye JY, Li S, Gladman DD, Chandran V.

Ann Rheum Dis. 2018 Aug 4. pii: annrheumdis-2018-213334. doi: 10.1136/annrheumdis-2018-213334. [Epub ahead of print]

PMID:
30077991
2.

Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?

Tselios K, Gladman DD, Harvey P, Akhtari S, Su J, Urowitz MB.

J Rheumatol. 2018 Aug 1. pii: jrheum.171436. doi: 10.3899/jrheum.171436. [Epub ahead of print]

PMID:
30068764
3.

Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.

Keeling SO, Bissonauth A, Bernatsky S, Vandermeer B, Fortin PR, Gladman DD, Peschken C, Urowitz MB.

J Rheumatol. 2018 Aug 1. pii: jrheum.171307. doi: 10.3899/jrheum.171307. [Epub ahead of print]

4.

The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis.

Zhou W, Chandran V, Cook R, Gladman DD, Eder L.

Semin Arthritis Rheum. 2018 Jun 19. pii: S0049-0172(18)30152-5. doi: 10.1016/j.semarthrit.2018.06.001. [Epub ahead of print]

PMID:
30057322
5.

Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720. [Epub ahead of print]

PMID:
30055090
6.

Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Manzi S, Nived O, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Stoll T, Buyon J, Mahler M, Fritzler MJ.

Arthritis Care Res (Hoboken). 2018 Jul 25. doi: 10.1002/acr.23712. [Epub ahead of print]

PMID:
30044551
7.

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.

Gladman DD, Kavanaugh A, Gómez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Guerette B, Delev N, Teng L, Edwards CJ, Birbara CA, Mease PJ.

RMD Open. 2018 Jun 27;4(1):e000669. doi: 10.1136/rmdopen-2018-000669. eCollection 2018.

8.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Jun 25. doi: 10.1093/rheumatology/key161. [Epub ahead of print]

PMID:
29945203
9.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2018 Jun 18. pii: S0190-9622(18)32149-2. doi: 10.1016/j.jaad.2018.06.027. [Epub ahead of print] Review.

PMID:
29928910
10.

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Scarpa R, Marchesoni A, Taylor WJ, Salvarani C, Kalden J, Lubrano E, Carneiro S, Piga M, Floris A, Desiati F, Flynn JA, D'Angelo S, van Kuijk AWR, Catanoso MG, Caso F, Contu P, Ujfalussy I, Helliwell PS, Mease PJ; for the GRAPPA 3PPsA Study Group.

J Rheumatol. 2018 Jun 15. pii: jrheum.171183. doi: 10.3899/jrheum.171183. [Epub ahead of print]

PMID:
29907666
11.

Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:54-61. doi: 10.3899/jrheum.180141.

PMID:
29858357
12.

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

Gladman DD, Coates LC, Jadon DR, Tillett W, Mease PJ, Vis M.

J Rheumatol Suppl. 2018 Jun;94:26-29. doi: 10.3899/jrheum.180132.

PMID:
29858349
13.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
14.

Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Helliwell PS, Gladman DD, Gottlieb AB.

J Rheumatol Suppl. 2018 Jun;94:1-3. doi: 10.3899/jrheum.180129.

PMID:
29858345
15.

Monophasic Disease Course in Systemic Lupus Erythematosus.

Tselios K, Gladman DD, Touma Z, Su J, Anderson N, Urowitz MB.

J Rheumatol. 2018 Aug;45(8):1131-1135. doi: 10.3899/jrheum.171319. Epub 2018 Jun 1.

PMID:
29858240
16.

Patterns of peripheral joint involvement in psoriatic arthritis-Symmetric, ray and/or row?

Chandran V, Stecher L, Farewell V, Gladman DD.

Semin Arthritis Rheum. 2018 Mar 9. pii: S0049-0172(17)30705-9. doi: 10.1016/j.semarthrit.2018.03.002. [Epub ahead of print]

PMID:
29724452
17.

A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index.

Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB.

Rheumatology (Oxford). 2018 Aug 1;57(8):1370-1376. doi: 10.1093/rheumatology/key103.

PMID:
29688532
18.

Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors.

Tselios K, Gladman DD, Harvey P, Su J, Urowitz MB.

Lupus. 2018 Aug;27(9):1415-1423. doi: 10.1177/0961203318770526. Epub 2018 Apr 17.

PMID:
29665757
19.

Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies.

Tanwani J, Tselios K, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Jul;27(8):1296-1302. doi: 10.1177/0961203318770018. Epub 2018 Apr 11.

PMID:
29642752
20.

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA).

Mease PJ, Gladman DD, Samad AS, Coates LC, Liu LXH, Aras GA, Collier DH, Chung JB.

RMD Open. 2018 Feb 3;4(1):e000606. doi: 10.1136/rmdopen-2017-000606. eCollection 2018.

21.

Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study.

Eder L, Harvey P, Chandran V, Rosen CF, Dutz J, Elder JT, Rahman P, Ritchlin CT, Rohekar S, Hayday R, Barac S, Feld J, Zisman D, Gladman DD.

J Rheumatol. 2018 Mar;45(3):378-384. doi: 10.3899/jrheum.170379. Epub 2018 Feb 1.

PMID:
29419462
22.

Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN.

Rheumatology (Oxford). 2018 Apr 1;57(4):677-687. doi: 10.1093/rheumatology/kex444.

PMID:
29361147
23.

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.

Touma Z, Gladman DD.

Lupus Sci Med. 2017 Dec 17;4(1):e000239. doi: 10.1136/lupus-2017-000239. eCollection 2017. Review.

24.

Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus.

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PR, Yelin EH, Ginzler E, Hanly JG, Peschken C, Gordon C, Nived O, Aranow C, Bae SC, Isenberg D, Rahman A, Hansen JE, Pierre YS, Clarke AE.

J Rheumatol. 2018 Mar;45(3):393-396. doi: 10.3899/jrheum.170652. Epub 2018 Jan 15.

PMID:
29335347
25.

Cerebrovascular Events in Systemic Lupus Erythematosus.

Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin P, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Steinsson K, Ramsey-Goldman R, Zoma AA, Manzi S, Nived O, Jonsen A, Khamashta MA, Alarcón GS, Chatham W, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Ramos-Casals M, Lim SS, Inanc M, Kalunian KC, Jacobsen S, Peschken CA, Kamen DL, Askanase A, Theriault C, Farewell V.

Arthritis Care Res (Hoboken). 2018 Jan 5. doi: 10.1002/acr.23509. [Epub ahead of print]

PMID:
29316357
26.

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).

van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, Shuler CL, Carlier H, Benichou O, Mease PJ.

J Rheumatol. 2018 Mar;45(3):367-377. doi: 10.3899/jrheum.170429. Epub 2017 Dec 15.

27.

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.

Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD.

RMD Open. 2017 Jul 18;3(1):e000415. doi: 10.1136/rmdopen-2016-000415. eCollection 2017.

28.

Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia.

AlJohani R, Polachek A, Ye JY, Chandran V, Gladman DD.

J Rheumatol. 2018 Feb;45(2):213-217. doi: 10.3899/jrheum.170384. Epub 2017 Dec 1.

PMID:
29196385
29.

Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach.

Barber MRW, Hanly JG, Su L, Urowitz MB, Pierre YS, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Fortin PR, Gladman DD, Sanchez-Guerrero J, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V, Clarke AE.

Arthritis Care Res (Hoboken). 2017 Nov 28. doi: 10.1002/acr.23480. [Epub ahead of print]

PMID:
29193883
30.

Addressing comorbidities in psoriatic disease.

Patel P, Rosen CF, Chandran V, Ye YJ, Gladman DD.

Rheumatol Int. 2018 Feb;38(2):219-227. doi: 10.1007/s00296-017-3895-y. Epub 2017 Nov 28.

PMID:
29185085
31.

Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis.

Abji F, Pollock RA, Liang K, Chandran V, Gladman DD.

Clin Exp Rheumatol. 2018 May-Jun;36(3):486-489. Epub 2017 Nov 9.

PMID:
29148410
32.

More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus.

Pakchotanon R, Gladman DD, Su J, Urowitz MB.

J Rheumatol. 2018 Jan;45(1):90-94. doi: 10.3899/jrheum.170645. Epub 2017 Nov 15.

PMID:
29142038
33.

Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study.

Tselios K, Gladman DD, Su J, Ace O, Urowitz MB.

J Rheumatol. 2017 Dec;44(12):1841-1849. doi: 10.3899/jrheum.161121. Epub 2017 Nov 1.

PMID:
29093154
34.

Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease.

Eder L, Joshi AA, Dey AK, Cook R, Siegel EL, Gladman DD, Mehta NN.

Arthritis Rheumatol. 2018 Mar;70(3):408-416. doi: 10.1002/art.40366. Epub 2018 Feb 6.

PMID:
29088580
35.

Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis.

Tselios K, Lam WC, Urowitz MB, Gladman DD.

J Clin Rheumatol. 2018 Mar;24(2):93-94. doi: 10.1097/RHU.0000000000000600. No abstract available.

PMID:
29059086
36.

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative.

Højgaard P, Klokker L, Orbai AM, Holmsted K, Bartels EM, Leung YY, Goel N, de Wit M, Gladman DD, Mease P, Dreyer L, Kristensen LE, FitzGerald O, Tillett W, Gossec L, Helliwell P, Strand V, Ogdie A, Terwee CB, Christensen R.

Semin Arthritis Rheum. 2018 Apr;47(5):654-665. doi: 10.1016/j.semarthrit.2017.09.002. Epub 2017 Sep 9. Review.

PMID:
29037523
37.

Antimalarial-induced cardiomyopathy: a systematic review of the literature.

Tselios K, Deeb M, Gladman DD, Harvey P, Urowitz MB.

Lupus. 2018 Apr;27(4):591-599. doi: 10.1177/0961203317734922. Epub 2017 Oct 9.

PMID:
28992800
38.

Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.

Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Callis Duffin K, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Hüffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Löhr S, Mrowietz U, Müller-Nurayid M, Nöthen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN.

Hum Mol Genet. 2017 Nov 1;26(21):4301-4313. doi: 10.1093/hmg/ddx328.

39.

Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.

Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD.

J Med Econ. 2018 Feb;21(2):163-173. doi: 10.1080/13696998.2017.1384737. Epub 2017 Oct 19.

PMID:
28945143
40.

Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis.

Pakchotanon R, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Mar;27(3):468-474. doi: 10.1177/0961203317726376. Epub 2017 Aug 31.

PMID:
28857717
41.

The association between sonographic enthesitis and radiographic damage in psoriatic arthritis.

Polachek A, Cook R, Chandran V, Gladman DD, Eder L.

Arthritis Res Ther. 2017 Aug 15;19(1):189. doi: 10.1186/s13075-017-1399-5.

42.

Association of variably expressed KIR3dl1 alleles with psoriatic disease.

Berinstein J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Gladman DD.

Clin Rheumatol. 2017 Oct;36(10):2261-2266. doi: 10.1007/s10067-017-3784-5. Epub 2017 Aug 11.

PMID:
28801811
43.

Shrinking lung syndrome in systemic lupus erythematosus: a single-centre experience.

Deeb M, Tselios K, Gladman DD, Su J, Urowitz MB.

Lupus. 2018 Mar;27(3):365-371. doi: 10.1177/0961203317722411. Epub 2017 Jul 31.

PMID:
28758573
44.

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies.

Tillett W, Orbai AM, Ogdie A, Leung YY, Strand V, Gladman DD, Mease PJ, Coates LC; GRAPPA OMERACT Psoriatic Arthritis working group.

Ann Rheum Dis. 2018 May;77(5):e23. doi: 10.1136/annrheumdis-2017-212004. Epub 2017 Jul 26. No abstract available.

PMID:
28747326
45.

Transancestral mapping and genetic load in systemic lupus erythematosus.

Langefeld CD, Ainsworth HC, Cunninghame Graham DS, Kelly JA, Comeau ME, Marion MC, Howard TD, Ramos PS, Croker JA, Morris DL, Sandling JK, Almlöf JC, Acevedo-Vásquez EM, Alarcón GS, Babini AM, Baca V, Bengtsson AA, Berbotto GA, Bijl M, Brown EE, Brunner HI, Cardiel MH, Catoggio L, Cervera R, Cucho-Venegas JM, Dahlqvist SR, D'Alfonso S, Da Silva BM, de la Rúa Figueroa I, Doria A, Edberg JC, Endreffy E, Esquivel-Valerio JA, Fortin PR, Freedman BI, Frostegård J, García MA, de la Torre IG, Gilkeson GS, Gladman DD, Gunnarsson I, Guthridge JM, Huggins JL, James JA, Kallenberg CGM, Kamen DL, Karp DR, Kaufman KM, Kottyan LC, Kovács L, Laustrup H, Lauwerys BR, Li QZ, Maradiaga-Ceceña MA, Martín J, McCune JM, McWilliams DR, Merrill JT, Miranda P, Moctezuma JF, Nath SK, Niewold TB, Orozco L, Ortego-Centeno N, Petri M, Pineau CA, Pons-Estel BA, Pope J, Raj P, Ramsey-Goldman R, Reveille JD, Russell LP, Sabio JM, Aguilar-Salinas CA, Scherbarth HR, Scorza R, Seldin MF, Sjöwall C, Svenungsson E, Thompson SD, Toloza SMA, Truedsson L, Tusié-Luna T, Vasconcelos C, Vilá LM, Wallace DJ, Weisman MH, Wither JE, Bhangale T, Oksenberg JR, Rioux JD, Gregersen PK, Syvänen AC, Rönnblom L, Criswell LA, Jacob CO, Sivils KL, Tsao BP, Schanberg LE, Behrens TW, Silverman ED, Alarcón-Riquelme ME, Kimberly RP, Harley JB, Wakeland EK, Graham RR, Gaffney PM, Vyse TJ.

Nat Commun. 2017 Jul 17;8:16021. doi: 10.1038/ncomms16021.

46.

From Childhood to Adulthood: Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus.

Lim LSH, Pullenayegum E, Feldman BM, Lim L, Gladman DD, Silverman ED.

Arthritis Care Res (Hoboken). 2018 May;70(5):750-757. doi: 10.1002/acr.23319. Epub 2018 Mar 25.

PMID:
28704581
47.

Magnetic Resonance Imaging in Psoriatic Arthritis: A Descriptive Study of Indications, Features and Effect on Treatment Change.

Maldonado-Ficco H, Sheane BJ, Thavaneswaran A, Chandran V, Gladman DD.

J Clin Rheumatol. 2017 Aug;23(5):243-245. doi: 10.1097/RHU.0000000000000558.

PMID:
28700527
48.

Reply.

Urowitz MB, Gladman DD.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1934. doi: 10.1002/acr.23309. No abstract available.

PMID:
28686813
49.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

50.

Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors.

Wong ITY, Chandran V, Li S, Gladman DD.

J Rheumatol. 2017 Sep;44(9):1369-1374. doi: 10.3899/jrheum.161330. Epub 2017 Jun 15.

PMID:
28620064

Supplemental Content

Loading ...
Support Center